Estrella Immunopharma Inc. (ESLA)
Healthcare
Biotechnology
0.71 $
-0.9%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Estrella Immunopharma Inc. (ESLA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 32.8% of the shares are freely tradable; institutional investors hold 12.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
12.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
60.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
32.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
0.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
43Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.53 | 4,099,000 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 1.04 | 448,765 | +6.9 | 12/31/2025 |
| Vanguard Capital Management, LLC | 0.89 | 382,469 | +0.0 | 03/31/2026 |
| Wells Fargo & Co | 0.61 | 264,388 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 0.37 | 157,485 | +43.4 | 03/31/2026 |
| Vanguard Fiduciary Trust Co | 0.15 | 64,921 | +0.0 | 03/31/2026 |
| Renaissance Technologies Corp | 0.15 | 62,795 | -48.7 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 0.62 | 268,005 | +0.0 | 04/30/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.34 | 148,247 | +29.5 | 04/30/2026 |
| Fidelity Extended Market Index | 0.24 | 105,115 | -0.4 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.